

## CLINICIAN INVESTIGATOR ADVANCEMENT PROGRAMME

### Objective:

**To support independent Clinician Investigators (CIVs) to further develop and mature their research programme to the next level and to provide protected time dedicated to their research programme.**

### General Information

1. A Clinician Investigator (CIV) is defined as an individual who conducts clinical research, translational research, health services research, epidemiology research, clinical trials and innovation etc, or a combination of these areas. The CIV's research and innovation efforts are supported by a range of funding such as from National Medical Research Council (NMRC) non-talent development grants, philanthropy funding, etc. CIVs can be part of the SingHealth Duke-NUS Academic Clinical Programme (ACP), SingHealth Duke-NUS Disease Centre (SDDC) / Duke-NUS Signature Research Programme (SRP) and be a Co-I or collaborator with a Clinician Scientist (CS) and/or Basic Scientist.
2. An established CIV is envisioned to:
  - i) Lead a focused research programme / platform
  - ii) Have funding to support the research programme / platform
  - iii) Have a range of collaborators
  - iv) Have a team of support staff, such as Clinical Research Coordinators (CRCs) etc.
  - v) Produce good research output in terms of publications, trial participation, innovation and driving clinical services from their research findings
  - vi) Be a mentor and nurture emerging researchers
3. The CIV Advancement (CIVA) Programme is a **prestigious award** to give recognition and **support to CIVs who have plans to further develop and grow their research platform / team / focus**. This initiative aims to:
  - i) Optimise the research output of productive CIVs
  - ii) Grow the research programme / platform of CIVs
  - iii) Build the support team of CIVs
  - iv) Establish the reputation and profile of CIVs
4. The award does not come with funding support but offers valuable **protected time of 0.2 FTE** to provide the opportunity for the CIVs to optimise their research platform and efforts. The 0.2 FTE will allow the awardee to:
  - i) Apply and obtain grants, trial revenue and philanthropic funding
  - ii) Optimise research outcomes including publications and presentations
  - iii) Grow the reputation and profile of the CIV and his / her research platform
  - iv) Become a mentor for emerging academic clinicians
  - v) Build collaborations within the AMC, nationally and internationally
5. The applicant will have to work with his / her Clinical HOD, ACP Chair, SDDC Head (where applicable) to structure the use of the awarded 0.2 FTE in a manner that is appropriate for the

applicant's research work.

6. The CIV Advancement Programme has a **fixed tenure of 2 years** with the possibility to **renew once**.
7. The CIV Advancement Programme provides the opportunity for successful awardees to become independent established clinician researchers of international standing, having adequate time to pursue and advance their research, to be supported by various grants, leading / co-leading research platforms, becoming a key partner for other researchers and a clinician leader in the AMC, ultimately translating research findings into clinical care.

### Application Requirements & Evaluation Criteria

8. Each submission must be made using the prescribed forms:
  - i) CIV Advancement Programme Application Form (to be completed by applicant)
  - ii) Applicant CV & Career Development Plan (to be completed by applicant)
  - iii) Nomination Form (to be completed and endorsed by Clinical HOD, ACP Chair and SDDC Head (where applicable)).

Failure to comply with the requirements and/or an incomplete application will result in disqualification from review.
9. Proposals should define **clear and measurable** deliverables / outcomes and **should be greater than the current research output**. This may include:
  - i) Funding support
  - ii) Collaborations locally and internationally
  - iii) Publications
  - iv) Clinical trial participation
  - v) Development of specific research projects
  - vi) Research manpower within your team
10. For applicants who are planning to apply for **national level funding**, are already holding national grants, or are supported by clinical trials etc., please state the justification for the need of protected time in your application for the Clinician Investigator Advancement Programme.
11. All submitted documents and data therein will be made available to any persons who are reasonably required to review, evaluate, recommend, and approve the award. They shall also subsequently be used to facilitate administration, talent management and development within the SingHealth Duke-NUS Academic Medical Centre.
12. For shortlisted applicants, a short interview with the review panel may be required. Details concerning the interview will be disseminated once it is finalised.
13. For successful applicants, the outcomes of the research programme / platform will be monitored during and after the award tenure. Applicants are expected to submit these periodically during and after the tenure of the award.